- Home
- ALEC
ALEC
Alector Inc.
as 12-20-2024 3:30pm EST
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 232.6M | IPO Year: | 2019 |
| Target Price: | $11.75 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.73 - $8.90 | Next Earning Date: | 11-06-2024 |
| Revenue: | $61,508,000 | Revenue Growth: | -36.14% |
| Revenue Growth (this year): | -33.75% | Revenue Growth (next year): | 71.71% |
Stock Insider Trading Activity of Alector Inc. (ALEC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rosenthal Arnon | ALEC | Chief Executive Officer | Dec 2 '24 | Sell | $2.52 | 52,172 | $131,442.14 | 2,507,074 | |
| Romano Gary | ALEC | Chief Medical Officer | Dec 2 '24 | Sell | $2.52 | 14,892 | $37,518.90 | 349,283 | |
| GRASSO MARC | ALEC | Chief Financial Officer | Dec 2 '24 | Sell | $2.52 | 16,489 | $41,542.39 | 330,651 | |
| Kenkare-Mitra Sara | ALEC | President and Head of R&D | Dec 2 '24 | Sell | $2.52 | 26,500 | $66,764.10 | 565,215 |
Latest Alector Inc. News
ALEC Breaking Stock News: Dive into ALEC Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Mizuho Downgrades Alector to Neutral From Outperform, Cuts Price Target to $2.50 From $9
MT Newswires
6 days ago
Stifel Downgrades Alector to Hold From Buy, Adjusts Price Target to $4 From $15
MT Newswires
18 days ago
BofA Securities Downgrades Alector to Underperform
Zacks
25 days ago
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
TipRanks
25 days ago
Alector price target lowered to $7 from $35 at H.C. Wainwright
Clinical Trials Arena
a month ago
Alector stock drops after Alzheimer’s drug fails in Phase II trial
BioPharma Dive
a month ago
Alector turns to layoffs as Alzheimer’s drug fails
GlobeNewswire
a month ago
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
Compare ALEC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALEC Alector Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.